SCHEMBL29471232

SCHEMBL29471232

Cc1cc2c(N3CCN(C)c4cc(-c5cnn(C)c5)c(C#N)cc43)cc(OCCN3CCN(C(=O)OC(C)(C)C)CC3)cc2n(C)c1=O

nearest known ligand 0.42

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 16/20 0.42
▸ SQOR Q9Y6N5 1/20 0.40
▸ NSD2 O96028 1/20 0.36
▸ GPR4 P46093 1/20 0.36
▸ LRRK2 Q5S007 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26548437 1.00 RET (0.42) RETSQORNSD2GPR4LRRK2
SCHEMBL29471212 0.92 GRM4 (0.38) RET
SCHEMBL29029078 0.92 RET (0.35) RET
SCHEMBL24316690 0.92 GRM4 (0.38) RET
SCHEMBL26112024 0.90 CREBBP (0.36) RETSQOR
SCHEMBL24316581 0.88 RET (0.36) RET
SCHEMBL29471251 0.88 RET (0.36) RET
SCHEMBL31496193 0.87 RET (0.42) RET
SCHEMBL24316580 0.87 RET (0.37) RET
SCHEMBL29471231 0.86 CREBBP (0.37) RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4210683-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS Aurigene Oncology Limited (IN) 2023-07-19 — — EP disclosed
WO-2022053967-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2022-03-17 — — WO disclosed
Send feedback